You are here: Industry Insights > CANbridge

News List

Qiming's Portfolio Company CANbridge Pharmaceuticals Lists on Main Board of HKEx prnasia
December 13, 2021
Qiming Venture Partners' portfolio company CANbridge Pharmaceuticals (SEHK: 1228), a leading China-based global rare disease-focused biopharmaceutical company, today listed on the main board of Hong Kong, S.A.R., China Stock Exchange.
CANbridge signs license agreement with Mirum for maralixibat in Greater China pharmaceutical-business-review
May 07, 2021
Biopharmaceutical company CANbridge Pharmaceuticals has signed a licensing agreement with Mirum Pharmaceuticals for the development and commercialisation of maralixibat in Greater China.
CANbridge Appoints SVP, Rare Disease Commercial Operations contractpharma
July 31, 2019
Marcelo Cheresky brings nearly 20 years' business leadership experience in the biotechnology industry.
Boehringer Provides CMC Services for CANbridge contractpharma
August 28, 2018
Beijing-based CANbridge Life Sciences has received clinical trial application (CTA) approval from the China Food and Drug Administration (CFDA) to conduct clinical trials in China with its drug candidate CAN017.